Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05817851
PHASE2

Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock.

Sponsor: Centre Hospitalier de Bethune

View on ClinicalTrials.gov

Summary

Among patients admitted after an out-of-hospital cardiac arrest (OHCA) in intensive care unit (ICU), almost two thirds of patients will develop in the first hours a post-cardiac arrest (CA) shock. This post-CA shock, combines cardiac and hemodynamic failure, generally resulting in multi-organ failure and early death in up to 35% of patients. Experimental data suggest that intravenous ascorbic acid (vitamin C) may attenuate inflammation and vascular injury related to sepsis or surgery. Preclinical and clinical studies also provide safety data of high dose intravenous vitamin C (\> 200mg/kg/day) with no significant adverse event reported and favorable impact on outcome. Experimental data also suggest beneficial effect of vitamin C in post-CA management with improvement of shock and multi-organ failure with potential benefit on neuroprotection and outcome. The study is a phase II multicenter prospective controlled open-label trial randomized in two parallel groups : * Expérimental group: Standard of care care for post-CA shock + Vitamin C (Vit-C) 200mg/kg/d IV (started as early as possible, no later than 1 h after randomization + thiamin (Vit B1) 200mg every 12 h during 3 days. * Control group: Standard of care care for post CA shock according international guidelines. Patient number to be enrolled : 234, Study duration :24 months and 28 days, Inclusion duration : 24 months, Patient participation : duration : 28 days

Official title: Efficacy of Early Intravenous High-dose Vitamin C in Post-cardiac Arrest Shock: a Multicenter, Randomized Controled Trial.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

234

Start Date

2023-12-27

Completion Date

2028-01-24

Last Updated

2026-01-06

Healthy Volunteers

No

Conditions

Interventions

DRUG

Vitamin C (Laroscorbine) + Vitamin B1 (Bevitine)

in addition of standard post-CA as the control group, patients will receive an IV high-dose vit-C 50mg/kg infusion every 6 hours, started within the hour after randomization, for 3 days. In addition, all patients will receive intravenous thiamine 200 mg twice a day for 3 days to limit the oxalate production.

DRUG

standard treatment

no intervention Standard IV vit-C supplementation will be allowed for dosages up to 1000 mg a day from day 4 after randomization, as well as thiamin supplementation.

Locations (14)

Centre Hospitalier Universitaire d'Amiens

Amiens, France

CH d'Arras

Arras, France

Centre Hospitalier Béthune

Béthune, France

CHI Nord-Ardennes

Charleville-Mézières, France

Centre Hospitalier de Dieppe

Dieppe, France

GHEF Site Marne La Vallée

Jossigny, France

Centre Hospitalier de LENS

Lens, France

Centre Hospitalier Universitaire de LILLE

Lille, France

CH de Melun (GHSIF)

Melun, France

Hôpital Lariboisière

Paris, France

Centre Hospitalier de Rouen

Rouen, France

Centre Hospitalier Toulon La Seyne sur Mer

Toulon, France

Centre Hospitalier de Valenciennes

Valenciennes, France

CH de Versailles

Versailles, France